Icru 50

KiranRamakrishna 6,844 views 30 slides Dec 23, 2019
Slide 1
Slide 1 of 30
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30

About This Presentation

Icru 50


Slide Content

PRESCRIBING, RECORDING AND REPORTING PHOTON BEAM THERAPY ICRU REPORT 50 DR KIRAN

STEPS IN RADIOTHERAPY

When delivering a radiotherapy treatment , parameters such as volume and dose have to be specified for different purposes: prescription, recording, and reporting. It is important that clear, well defined and unambigous concepts and parameters are used for reporting purposes to ensure a common language between different centers.

AIM OF THERAPY Radical treatment of Malignant disease To achieve permanent tumor control Volumes to be treated is tumor and the expected subclinical disease. Palliative treatment of Malignant disease To decrease symptoms May include all or only part of the tumor Non-malignant diseases

ICRU 50 Volumes defined prior to treatment planning : - Gross Tumor Volume (GTV) - Clinical Target Volume (CTV) Volumes defined during the treatment planning : - Planning target Volume (PTV) - Organs at risk - Treated Volume - Irradiated Volume

GROSS TUMOR VOLUME ( GTV ) Gross palpable or visible/demonstrable extent and location of the malignant growth. It consists of : - Primary tumor - Metastatic lymphadenopathy - Other metastasis Corresponds to those parts of the malignant growth where the tumor density is largest. If the tumor has been removed prior to radiotherapy then no GTV can be defined.

GTV can be determined by using either clinical examination (inspection, palpation) and by various imaging techniques (X-rays, CT, MRI etc.) Method used for determination of GTV should meet the requirements for staging the tumor according to the clinical TNM (UICC and AJCCS).

Reasons for identification of GTV : An adequate dose should be delivered to the whole of GTV to obtain local tumor control in radical treatments. To allow for recording of tumor response in relation to dose and its variation, and to other relevant factors.

GTV

CLINICAL TARGET VOLUME ( CTV ) It is a tissue volume that contains a GTV and/or subclinical microscopic disease, which has to be eliminated. This volume has to be treated adequately in order to achieve the aim of therapy : cure or palliation. The delineation of this volume requires consideration of factors like local invasive capacity of the tumor and its potential to spread to different regions ( eg : regional lymph nodes).

CTV

PLANNING TARGET VOLUME ( PTV ) It is a geometrical concept, and is defined to select appropriate beam sizes and arrangements, taking into consideration the net effect of all possible geometrical variations, in order to ensure that the prescribed dose is actually absorbed in the CTV. It is used for dose planning and for specification of dose. It has to be clearly indicated on sections used for dose planning and the dose distribution to the PTV has to be considered to be representative of the dose to the CTV.

PTV

TREATED VOLUME It is a volume enclosed by an isodose surface (95 %), selected and specified by the radiation oncologist as being appropriate to achieve the purpose of treatment ( tumor eradication or palliation ). It may closely match to the PTV or may be larger than the PTV. If, however, it is smaller than the PTV, or not wholly enclosing the PTV, then the probability of tumor control is reduced and the treatment plan has to be reevaluated or the aim of the therapy has to be reconsidered.

Reasons for identification of Treated Volume are : The shape and size of the Treated Volume relative to the PTV is an important optimization parameter. Also, a recurrence within a Treated Volume but outside the PTV may be considered to be a “true”, “in-field” recurrence due to inadequate dose and not a “marginal” recurrence due to inadequate volume.

IRRADIATED VOLUME ( IrV ) It is that tissue volume which receives a dose that is considered significant in relation to normal tissue tolerance. It depends on the treatment technique used.

ORGANS AT RISK ( OR ) These are normal tissues whose radiation sensitivity may significantly influence the treatment planning and/or prescribed dose. They may be divided into 3 classes : Class I : Radiation lesions are fatal or result in severe morbidity. Class II : Radiation lesions result in mild to moderate morbidity. Class III : Radiation lesions are mild, transient, and reversible, or result in no significant morbidity.

ICRU 50 Irradiated Volume Treated Volume Planning Target Volume (PTV) Clinical Target Volume (CTV) Gross Tumor Volume (GTV)

INTERNAL MARGIN ( IM ) AND INTERNAL TARGET VOLUME ( ITV ) It is the margin given around the CTV to compensate for all variations in the site, size and shapes of organs and tissues contained in or adjacent to CTV. These may result from respiration, different fillings of the bladder and rectum, swallowing, heart beat, movements of bowel etc. These are physiological variations which are very difficult to control and result in changes in the site, size and shape of CTV.

SET-UP MARGIN ( SM ) There can be many uncertainties ( inaccuracies and lack of reproducibility ) in patient positioning and alignment of the therapeutic beams during treatment planning and through all treatment sessions. These uncertainties depend on factors like : variations in pt. positioning mechanical uncertainties of the equipment (sagging of gantry, collimators, and couch) dosimetric uncertainties transfer set-up errors from CT & simulator to the treatment unit human factors

ADSORBED DOSE DISTRIBUTION The dose given to the tumor should be as homogenous as possible. In cases of heterogeneity of doses, the outcome of the treatment cannot be related to the dose. Also, the comparison between different patient series becomes difficult. However, even if a perfectly homogenous dose distribution is desirable, some heterogeneity is accepted due to technical reasons. The heterogeneity should be foreseen while prescribing a treatment, and, in the best technical and clinical conditions should be kept within +7% and -5% of prescribed dose.

MAXIMUM DOSE ( D max ) It is the maximum dose to the PTV and the Organ at Risk. The maximum dose to normal tissue is important for limiting and for evaluating the side-effects of treatment. Dose is reported as maximum only when a volume of tissue of diameter more than 15mm is involved (smaller volumes are considered for smaller organs like eye, optic nerve, larynx). When the maximum dose outside PTV exceeds the prescribed dose, then a “Hot Spot” can be identified.

MINIMUM DOSE ( D min ) It is the smallest dose in a defined volume. In contrast to maximum adsorbed dose, no volume limit is recommended when reporting minimum dose.

HOT SPOTS It represents a volume outside the PTV which receives a dose larger than 100% of the specified dose. A Hot Spot is considered significant only if the minimum diameter exceeds 15mm (in smaller organs like eye, optical nerve, larynx etc. a diameter smaller than 15mm is also considered significant).

ICRU REFERENCE POINT It has to be selected according to the following general criteria : - the dose at the point should be clinically relevant. - the point should be easy to define in a clear and unambiguous way. - the point should be selected so that the dose should be accurately determined. - the point should be in a region where there is no steep dose gradient.

The recommendations will be fulfilled if the ICRU reference point is located : always at the center ( or in the central part ) of PTV, and when possible, at the intersection of the beam axes.

ICRU REFERENCE DOSE It is the dose at the ICRU Reference Point and should always be reported. REPORTING It should be done in order to make exchange of information between different centers. It is important that the treatments performed in various centers be reported in the same way, using the same concepts and definitions.

According to the recommendations of ICRU, as a basic requirement, the following doses should always be reported : the dose at ICRU reference point the maximum dose to the PTV the minimum dose to the PTV

CONCLUSIONS Proper identification and delineation of GTV is the most important factor in treatment. Other volumes like CTV, PTV, ITV should also be properly delineated. The errors like set-up error and human errors should be kept to a minimum. Dose prescription, fractionation and calculation should be done in the same way by all the different centers throughout the world for the proper exchange of information and reporting.

Thank you
Tags